Brief: Pharma Equity Group's Subsidiary Meets Primary Endpoints In Phase-2 Clinical Trial

Pharma Equity A/S

16/11/2023 14:03

Nov 16 (Reuters) - Pharma Equity Group A/S  PEGRP.CO :
    * PHARMA EQUITY GROUP'S SUBSIDIARY (REPONEX PHARMACEUTICALS
A/S)
MEETS THE PRIMARY ENDPOINTS IN THE PHASE-2 CLINICAL TRIAL OF THE
DRUG CANDIDATE RNX-051
    * REPONEX'S MEFO-TRIAL CONCERNS TREATMENT OF PATIENTS WITH
RIGHT-SIDED COLON CANCER AND RIGHT-SIDED COLON POLYPS/ADENOMAS
WITH CO'S DRUG CANDIDATE RNX-051
    * COMPLETE ANALYSIS OF STUDY'S RESULTS IS EXPECTED TO BE
READY
EARLY IN 2024

Source text for Eikon:  ID:nGNE4rht7x 
Further company coverage:  PEGRP.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))